This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Siris, S. G. Search for Related Content PubMed PubMed Citation Articles by Siris, S. G. Pubmed/NCBI databases Medline Plus Health Information Schizophrenia Suicide Social Bookmarking                         What's this?

Suicide and schizophrenia

Department of Psychiatry, Hillside Hospital Division of the North Shore, Long Island Jewish Health System and The Albert Einstein College of Medicine, New York 11004, USA; siris{at}LIJ.edu

Suicide and suicide attempts occur at a significantly greater rate in schizophrenia than in the general population. Common estimates are that 10% of people with schizophrenia will eventually have a completed suicide, and that attempts are made at two to five times that rate. Demographically associated with suicidality in schizophrenia are being young, being early in the course of the illness, being male, coming from a high socioeconomic family background, having high intelligence, having high expectations, not being married, lacking social supports, having awareness of symptoms, and being recently discharged from the hospital. Also associated are reduced self-esteem, stigma, recent loss or stress, hopelessness, isolation, treatment non-compliance and substance abuse. Clinically, the most common correlates of suicidality in schizophrenia are depressive symptoms and the depressive syndrome, although severe psychotic and panic-like symptoms may contribute as well. This review specifically explores the issue of depression in schizophrenia, in relation to suicide, by organizing the differential diagnosis of this state and highlighting their potentially treatable or correctable causes. This differential diagnosis includes both acute and chronic disappointment reactions, the prodrome of an acute psychotic episode, neuroleptic induced akinesia and akathisia, the possibility of direct neuroleptic-induced depression, negative symptoms of schizophrenia, and the possible co-occurrence of an independent depressive diathesis. The potential beneficial roles of ‘atypical’ antipsychotic agents, including both clozapine and more novel agents, and adjunctive treatment with other psychopharmacological medications are considered, and the important roles of psychosocial factors and interventions are recognized.

Key Words: assessment • depression • medication • prediction • psychopharmacology • schizophrenia • suicide • treatment

Journal of Psychopharmacology, Vol. 15, No. 2, 127-135 (2001)
DOI: 10.1177/026988110101500209


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. S. Weber, D. N. Cowan, A. M. Millikan, and D. W. Niebuhr Psychiatric and General Medical Conditions Comorbid With Schizophrenia in the National Hospital Discharge Survey Psychiatr Serv, August 1, 2009; 60(8): 1059 - 1067. [Abstract] [Full Text] [PDF]

				S. Bakst, J. Rabinowitz, and E. J. Bromet Antecedents and Patterns of Suicide Behavior in First-Admission Psychosis Schizophr Bull, March 9, 2009; (2009) sbp001v1. [Abstract] [Full Text] [PDF]

				K. Patel and R. Upthegrove Self-harm in first-episode psychosis Psychiatr. Bull., March 1, 2009; 33(3): 104 - 107. [Abstract] [Full Text] [PDF]

				P. F. Schulte Risk of Clozapine-Associated Agranulocytosis and Mandatory White Blood Cell Monitoring Ann. Pharmacother., April 1, 2006; 40(4): 683 - 688. [Abstract] [Full Text] [PDF]

				C. Griffiths and R. J. Flanagan Fatal poisoning with antipsychotic drugs, England and Wales 1993-2002 J Psychopharmacol, November 1, 2005; 19(6): 667 - 674. [Abstract] [PDF]

				K. HAWTON, L. SUTTON, C. HAW, J. SINCLAIR, and J. J. DEEKS Schizophrenia and suicide: systematic review of risk factors The British Journal of Psychiatry, July 1, 2005; 187(1): 9 - 20. [Abstract] [Full Text] [PDF]

				M. Bourgeois, J. Swendsen, F. Young, X. Amador, S. Pini, G. B. Cassano, J.-P. Lindenmayer, C. Hsu, L. Alphs, H. Y. Meltzer, et al. Awareness of Disorder and Suicide Risk in the Treatment of Schizophrenia: Results of the International Suicide Prevention Trial Am J Psychiatry, August 1, 2004; 161(8): 1494 - 1496. [Abstract] [Full Text] [PDF]

				R. Freedman Schizophrenia N. Engl. J. Med., October 30, 2003; 349(18): 1738 - 1749. [Full Text] [PDF]

				H. Y. Meltzer, L. Alphs, A. I. Green, A. C. Altamura, R. Anand, A. Bertoldi, M. Bourgeois, G. Chouinard, M. Z. Islam, J. Kane, et al. Clozapine Treatment for Suicidality in Schizophrenia: International Suicide Prevention Trial (InterSePT) Arch Gen Psychiatry, January 1, 2003; 60(1): 82 - 91. [Abstract] [Full Text] [PDF]